AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice
AUAUniversity4 Jun 2025

AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice

AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/43015 At the conclusion of this activity, participants will be able to: 1. Describe key components of genetic risk assessment, genetic counseling, and informed consent for genetic testing. 2. Describe elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability. 3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic results in prostate cancer screening and management of both localized and advanced prostate cancer. 4. Describe genetic causes, clinical manifestations, indication for genetic testing, and cancer risk associated with hereditary kidney cancer syndromes. Understand how genetic mutation can guide targeted therapy in patients with von Hippel-Lindau syndrome. 5. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Episoder(422)

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

29 Okt 201837min

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer is the second in the 4-part series. Topics will include "non muscle invasive disease" and "muscle invasive disease" as well as "clinical trial evidence" and ...

24 Okt 201854min

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

Speakers: Christopher M. Gonzalez, MD, MBA James M. Dupree, MD, MPH

22 Okt 201817min

Incorporating New IO Therapies - Managing Patient Side Effects

Incorporating New IO Therapies - Managing Patient Side Effects

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

19 Okt 201830min

Immuno - Oncoloy: A New Class Of Drugs

Immuno - Oncoloy: A New Class Of Drugs

Immuno-Oncology: A New Class of Drugs is the first in the 4-part series. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal ...

10 Okt 201842min

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third podcast in a 4-part series. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthe...

8 Okt 201856min

Incorporating New IO Therapies - Biomarkers

Incorporating New IO Therapies - Biomarkers

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

4 Okt 201829min

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation are producing a serie...

28 Sep 201851min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
rss-strid-de-norske-borgerkrigene
foreldreradet
jakt-og-fiskepodden
rss-sunn-okonomi
merry-quizmas
gravid-uke-for-uke
fryktlos
sinnsyn
smart-forklart
rss-mann-i-krise-med-sagen
hverdagspsyken
rss-kunsten-a-leve
dopet
aldring-og-helse-podden
rss-adhd-i-klasserommet
generasjonspodden